RTW Biotech Opportunities Ltd on Tuesday said that it has made several new investments in private portfolio companies, named Mirador Therapeutics and Santa Ana Bio.
RTW Biotech is an investment fund, managed by RTW Investments LP, that specialises in acquiring transformative assets across the life sciences sector. Shares in the firm were trading 0.7% lower at $1.52 each in London on Tuesday morning.
Mirador Therapeutics is a next-generation precision medicine company focused on immunology and inflammation, while Santa Ana Bio is a biotechnology company developing a pipeline of therapeutics to unlock the full potential of precision medicines.
Alongside other investment vehicles, RTW Biotech participated in Mirador’s Series A financing round, which raised over $400 million for its launch in March.
It also participated in Santa Ana’s Series A financing round, which raised $168 million in May.
‘We are active again in private investing and seeing a lot of opportunity. After a couple of years of slower deployment as we focused on opportunities in the public market, we now expect to head back to our normal pace of about a dozen private deals per year, especially if the IPO window continues to trend positively,’ said Chief Investment Officer Rod Wong.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
